MX359410B - Minicélulas intactas derivadas bacterialmente para suministro de agentes terapéuticos a tumores cerebrales. - Google Patents
Minicélulas intactas derivadas bacterialmente para suministro de agentes terapéuticos a tumores cerebrales.Info
- Publication number
- MX359410B MX359410B MX2014006967A MX2014006967A MX359410B MX 359410 B MX359410 B MX 359410B MX 2014006967 A MX2014006967 A MX 2014006967A MX 2014006967 A MX2014006967 A MX 2014006967A MX 359410 B MX359410 B MX 359410B
- Authority
- MX
- Mexico
- Prior art keywords
- minicells
- brain tumors
- bacterially derived
- delivery
- therapeutic agents
- Prior art date
Links
- 208000003174 Brain Neoplasms Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000012202 endocytosis Effects 0.000 abstract 1
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 238000007910 systemic administration Methods 0.000 abstract 1
- 230000031998 transcytosis Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a una composición para usarse en el tratamiento de un tumor cerebral, en donde la composición comprende una pluralidad de minicélulas bacterianamente derivadas, intactas, en donde cada minicélula de dicha pluralidad: (a) comprende un anticuerpo que reconoce específicamente un antígeno de célula de tumor, y (b) comprende un agente antineoplástico, y en donde la pluralidad de minicélulas entra al cerebro pasivamente a través de la barrera hematoencefálica (BBB) y el tumor cerebral comprende vasos sanguíneos con ventajes a través de los cuales las minicélulas extravasan pasivamente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569907P | 2011-12-13 | 2011-12-13 | |
| PCT/IB2012/002950 WO2013088250A1 (en) | 2011-12-13 | 2012-12-12 | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014006967A MX2014006967A (es) | 2014-12-05 |
| MX359410B true MX359410B (es) | 2018-09-27 |
Family
ID=48611925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014006967A MX359410B (es) | 2011-12-13 | 2012-12-12 | Minicélulas intactas derivadas bacterialmente para suministro de agentes terapéuticos a tumores cerebrales. |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9844598B2 (es) |
| EP (1) | EP2790668B1 (es) |
| JP (2) | JP6522340B2 (es) |
| KR (2) | KR102046042B1 (es) |
| CN (2) | CN104114153A (es) |
| AU (2) | AU2012351743B2 (es) |
| CA (1) | CA2858315C (es) |
| CY (1) | CY1123824T1 (es) |
| DK (1) | DK2790668T3 (es) |
| ES (1) | ES2843402T3 (es) |
| HK (1) | HK1201473A1 (es) |
| HR (1) | HRP20201930T1 (es) |
| HU (1) | HUE052136T2 (es) |
| IL (1) | IL233031B (es) |
| LT (1) | LT2790668T (es) |
| MX (1) | MX359410B (es) |
| PT (1) | PT2790668T (es) |
| RS (1) | RS61161B1 (es) |
| RU (1) | RU2664698C2 (es) |
| SG (2) | SG10201601349XA (es) |
| SI (1) | SI2790668T1 (es) |
| TW (1) | TWI627966B (es) |
| WO (1) | WO2013088250A1 (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2516056C (en) * | 2003-01-06 | 2012-05-29 | Angiochem Inc. | Aprotinin and analogs as carriers across the blood-brain barrier |
| US9365634B2 (en) * | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| EP2279008B1 (en) | 2008-04-18 | 2019-03-06 | Angiochem Inc. | Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use |
| AU2009304560A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of GLP-1 agonists and uses thereof |
| CN102245636A (zh) | 2008-10-15 | 2011-11-16 | 安吉奥开米公司 | 用于药物递送的依托泊苷和多柔比星结合物 |
| MX2011005963A (es) | 2008-12-05 | 2011-09-01 | Angiochem Inc | Conjugados de neurotensina o analogos de neurotensina y sus usos. |
| US8853353B2 (en) | 2008-12-17 | 2014-10-07 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| CA2759129C (en) | 2009-04-20 | 2018-12-11 | Angiochem Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
| AU2010268726A1 (en) | 2009-07-02 | 2012-01-19 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| SG11201401196WA (en) | 2011-10-03 | 2014-05-29 | Moderna Therapeutics Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| EP2790668B1 (en) * | 2011-12-13 | 2020-09-09 | EnGeneIC Molecular Delivery Pty Ltd. | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
| SG10201604896TA (en) | 2011-12-16 | 2016-08-30 | Moderna Therapeutics Inc | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| WO2013151670A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of nuclear proteins |
| EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
| WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| JP2016530294A (ja) | 2013-09-03 | 2016-09-29 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | キメラポリヌクレオチド |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| EA032740B1 (ru) * | 2013-10-04 | 2019-07-31 | Энджинеик Молекьюлар Деливери Пти Лтд | Способ лечения опухоли у индивидуума и набор для осуществления способа |
| CN114099686B (zh) * | 2014-07-15 | 2024-04-16 | 约翰·霍普金斯大学 | 源自骨髓的抑制细胞的抑制和免疫检查点阻断 |
| CA2955250A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US20170210788A1 (en) | 2014-07-23 | 2017-07-27 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| WO2016051389A1 (en) * | 2014-10-03 | 2016-04-07 | Engeneic Molecular Delivery Pty Ltd | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
| EP3307326B9 (en) | 2015-06-15 | 2021-02-24 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| LT3394093T (lt) | 2015-12-23 | 2022-04-25 | Modernatx, Inc. | Ox40 ligandus koduojančių polinukleotidų naudojimo būdai |
| WO2017120612A1 (en) | 2016-01-10 | 2017-07-13 | Modernatx, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
| WO2018213731A1 (en) | 2017-05-18 | 2018-11-22 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof |
| DE102018220892A1 (de) * | 2018-12-04 | 2020-06-04 | Robert Bosch Gmbh | Vorrichtung und Verfahren zur Generierung von Labelobjekten für die Umgebung eines Fahrzeugs |
| MX2021006564A (es) * | 2018-12-10 | 2021-08-11 | Flagship Pioneering Innovations Vi Llc | Sistemas activos dinamicos acromosomicos. |
| US20230139944A1 (en) * | 2019-06-21 | 2023-05-04 | Board Of Regents, The University Of Texas System | Targeting alpha3beta1 integrin for treatment of cancer and other diseases |
| CN111001014B (zh) * | 2019-12-12 | 2022-04-22 | 四川大学华西医院 | 一种基于固定细菌做载体的抗肿瘤药物及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0222340Y2 (es) | 1986-11-18 | 1990-06-15 | ||
| US6962702B2 (en) | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
| JP2002541124A (ja) * | 1999-04-02 | 2002-12-03 | センター・フォー・モレキュラー・メディシン・アンド・イムノロジー | 子宮内膜症を検出する方法 |
| DE60011612T2 (de) | 1999-04-28 | 2005-07-07 | Board of Regents, The University of Texas System, Austin | Zusammensetzungen und Verfahren zur Krebsbehandlung durch die selektive Hemmung von VEGF |
| FR2793684B1 (fr) | 1999-05-17 | 2001-08-10 | Ethypharm Lab Prod Ethiques | Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant |
| US20030194798A1 (en) * | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| US20030203411A1 (en) * | 2001-06-05 | 2003-10-30 | Sabbadini Roger A. | Methods of minicell-based delivery |
| EP2302063B1 (en) | 2001-10-15 | 2016-05-04 | EnGeneIC Molecular Delivery Pty Ltd. | Intact minicells as vectors for DNA transfer and gene therapy in vitro and in vivo |
| US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US20040005700A1 (en) * | 2002-05-28 | 2004-01-08 | Surber Mark W. | Poroplasts |
| AU2003241024A1 (en) | 2002-05-29 | 2003-12-19 | Immunomedics, Inc. | Methods and compositions for radioimmunotherapy of brain and cns tumors |
| CA2494310A1 (en) * | 2002-08-01 | 2004-02-12 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
| AU2004297414C1 (en) | 2003-12-09 | 2009-06-25 | Engeneic Molecular Delivery Pty Ltd | Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells |
| US8772013B2 (en) | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| EP2992901B1 (en) | 2004-02-02 | 2019-10-23 | EnGeneIC Molecular Delivery Pty Ltd | Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| US7837998B2 (en) * | 2004-05-21 | 2010-11-23 | Nathaniel Lallatin | Anti-cancer activity of an anti-thymidine kinase monoclonal antibody |
| WO2006021894A2 (en) | 2004-08-26 | 2006-03-02 | Engeneic Gene Therapy Pty Limited | Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
| US20090110633A1 (en) | 2005-03-14 | 2009-04-30 | Shiladitya Sengupta | Nanocells for Diagnosis and Treatment of Diseases and Disorders |
| US8940871B2 (en) | 2006-03-20 | 2015-01-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting |
| CN101505768B (zh) * | 2006-06-23 | 2013-11-06 | 因詹尼克分子递送控股有限公司 | 通过完整的死亡细菌细胞将药物、治疗性核酸和功能性核酸靶向递送至哺乳动物细胞 |
| EP2076292A2 (en) * | 2006-10-25 | 2009-07-08 | Koninklijke Philips Electronics N.V. | Contrast agents for detecting prostate cancer |
| SG10201804257RA (en) | 2007-03-30 | 2018-06-28 | Engeneic Molecular Delivery Pty Ltd Au | Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells |
| EP2310502B1 (en) * | 2008-06-25 | 2016-02-10 | Vaxiion Therapeutics, LLC | Regulated genetic suicide mechanism compositions and methods |
| US8445637B2 (en) * | 2008-12-05 | 2013-05-21 | Abraxis Bioscience, Llc | SPARC binding peptides and uses thereof |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| CA2827443C (en) * | 2011-02-15 | 2021-07-06 | Vaxiion Therapeutics, Inc. | Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells |
| EP2790668B1 (en) | 2011-12-13 | 2020-09-09 | EnGeneIC Molecular Delivery Pty Ltd. | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
| CN112689511A (zh) | 2018-07-23 | 2021-04-20 | 安吉尼科分子传输公司 | 包含细菌源微细胞的组合物及其使用方法 |
-
2012
- 2012-12-12 EP EP12857452.2A patent/EP2790668B1/en active Active
- 2012-12-12 HU HUE12857452A patent/HUE052136T2/hu unknown
- 2012-12-12 RU RU2014128338A patent/RU2664698C2/ru active
- 2012-12-12 LT LTEP12857452.2T patent/LT2790668T/lt unknown
- 2012-12-12 CN CN201280069592.1A patent/CN104114153A/zh active Pending
- 2012-12-12 US US13/711,848 patent/US9844598B2/en active Active
- 2012-12-12 ES ES12857452T patent/ES2843402T3/es active Active
- 2012-12-12 KR KR1020197019600A patent/KR102046042B1/ko active IP Right Grant
- 2012-12-12 RS RS20201489A patent/RS61161B1/sr unknown
- 2012-12-12 JP JP2014546670A patent/JP6522340B2/ja active Active
- 2012-12-12 KR KR1020147019228A patent/KR20140102294A/ko active Application Filing
- 2012-12-12 PT PT128574522T patent/PT2790668T/pt unknown
- 2012-12-12 DK DK12857452.2T patent/DK2790668T3/da active
- 2012-12-12 SI SI201231862T patent/SI2790668T1/sl unknown
- 2012-12-12 SG SG10201601349XA patent/SG10201601349XA/en unknown
- 2012-12-12 WO PCT/IB2012/002950 patent/WO2013088250A1/en active Application Filing
- 2012-12-12 CN CN201811227385.XA patent/CN109125286A/zh active Pending
- 2012-12-12 CA CA2858315A patent/CA2858315C/en active Active
- 2012-12-12 SG SG11201403062YA patent/SG11201403062YA/en unknown
- 2012-12-12 MX MX2014006967A patent/MX359410B/es active IP Right Grant
- 2012-12-12 AU AU2012351743A patent/AU2012351743B2/en active Active
- 2012-12-13 TW TW101147186A patent/TWI627966B/zh active
-
2014
- 2014-06-09 IL IL233031A patent/IL233031B/en active IP Right Grant
-
2015
- 2015-03-02 HK HK15102092.6A patent/HK1201473A1/xx unknown
-
2017
- 2017-08-22 JP JP2017158959A patent/JP6594383B2/ja active Active
- 2017-10-05 AU AU2017239542A patent/AU2017239542B2/en active Active
- 2017-10-23 US US15/790,885 patent/US10994014B2/en active Active
-
2020
- 2020-11-13 CY CY20201101075T patent/CY1123824T1/el unknown
- 2020-12-03 HR HRP20201930TT patent/HRP20201930T1/hr unknown
-
2021
- 2021-03-25 US US17/212,995 patent/US11964021B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX359410B (es) | Minicélulas intactas derivadas bacterialmente para suministro de agentes terapéuticos a tumores cerebrales. | |
| Vinogradov et al. | Macrophages associated with tumors as potential targets and therapeutic intermediates | |
| Park et al. | Enhanced BBB permeability of osmotically active poly (mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease | |
| US11085044B2 (en) | miRNA for treatment of breast cancer | |
| Amaldoss et al. | Inorganic nanoparticle-based advanced cancer therapies: Promising combination strategies | |
| JP2015523355A5 (es) | ||
| JP2014534864A5 (es) | ||
| MX353567B (es) | Composiciones de nanoparticulas de lipidos para la entrega de oligonucleotidos antisentido. | |
| WO2008116053A3 (en) | Fap-activated chemotherapeutic compounds, and methods of use thereof | |
| WO2010059253A3 (en) | Methods and compositions for localized agent delivery | |
| WO2016210376A3 (en) | Therapeutic peptides and methods of use thereof | |
| WO2012107908A3 (en) | Nts-polyplex nanoparticles system for gene therapy of cancer | |
| WO2011130458A3 (en) | Rna aptamers against baff-r as cell-type specific delivery agents and methods for their use | |
| Saraf et al. | Topotecan liposomes: a visit from a molecular to a therapeutic platform | |
| WO2008109432A3 (en) | Therapeutic targeting of interleukins using sirna in neutral liposomes | |
| Wang et al. | Ceramide-graphene oxide nanoparticles enhance cytotoxicity and decrease HCC xenograft development: a novel approach for targeted cancer therapy | |
| WO2005023328A3 (en) | Methods for intradermal delivery of therapeutics agents | |
| Tran et al. | Systemic delivery of aptamer–drug conjugates for cancer therapy using enzymatically generated self-assembled DNA nanoparticles | |
| NZ718148A (en) | Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma | |
| WO2010085665A3 (en) | Targeted delivery system | |
| US20210338705A1 (en) | Encapsulation and high encapsulation efficiency of phosphorylated active agents in nanoparticles | |
| Manikkath et al. | Nanoparticulate strategies for the delivery of miRNA mimics and inhibitors in anticancer therapy and its potential utility in oral submucous fibrosis | |
| Montagner et al. | Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer | |
| Kazemi et al. | PNA-ATP aptamer-capped doxorubicin-loaded silica nanoparticles for targeted cancer therapy | |
| Loc et al. | Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |